Howard J E, Winn L C, Gottlieb C E, Grumet F C, Garratty G, Petz L D
Transfusion. 1982 Jul-Aug;22(4):269-72. doi: 10.1046/j.1537-2995.1982.22482251204.x.
The need for anti-complement (anti-C') activity in antiglobulin antisera (AHG) for the detection of clinically significant antibodies was evaluated during a three-year period. While performing routine compatibility testing using standard blood banking procedures, eight patients were found whose antibodies were detectable primarily or only by AHG containing anti-C' activity; monospecific anti-igG AHG gave weak or negative reactions. Seven of the antibodies were anti-jka or jkb. Two of the anti-jka antibodies were responsible for clinically unsuspected delayed hemolytic transfusion reactions. The anti-jkb antibody resulted in a shortened survival of incompatible 51Cr-labelled red blood cells. The incidence of such "complement-only" Kidd antibodies was 23 percent of all Kidd antibodies found. These data suggest that the omission of anti-C' in AHG in routine compatability testing could result in substantial risk of failure to detect clinically significant antibodies.
在三年期间,对用于检测具有临床意义抗体的抗球蛋白抗血清(AHG)中抗补体(anti-C')活性的需求进行了评估。在使用标准血库程序进行常规相容性检测时,发现8名患者的抗体主要或仅通过含有抗C'活性的AHG才能检测到;单特异性抗IgG AHG产生微弱或阴性反应。其中7种抗体为抗Jka或抗Jkb。两种抗Jka抗体导致了临床上未被怀疑的迟发性溶血性输血反应。抗Jkb抗体导致不相容的51Cr标记红细胞存活期缩短。此类“仅补体”基德抗体的发生率占所有已发现基德抗体的23%。这些数据表明,在常规相容性检测中AHG中省略抗C'可能会导致未能检测到具有临床意义抗体的重大风险。